Parathyroidectomy After Kidney Transplantation

Recruiting now · Not applicable

Conditions studied: Hyperparathyroidism, Kidney Transplantation Recipients

In brief

This study aims to clarify whether surgical treatment of persistent hyperparathyroidism after kidney transplantation offers clinically meaningful benefits compared with a conservative treatment strategy. Kidney transplant recipients (\>6 mo after transplantation) with persistent hyperparathyroidism (elevated PTH and either hypercalcemia or hypophosphatemia) will be randomized in a 1:1 ratio to either subtotal parathyroidectomy or conservative management according to standard clinical practice. The study is conducted as an open-label, randomized controlled pilot trial with a 12-month follow-up period. Outcomes include bone density, physical function, quality of life and symptom burden.

Key facts

Study ID

NCT07415421

Run by

Aarhus University Hospital

People needed

85

Starts

2026-03-03

Expected to finish

2030-12-31

Last updated by the study team

2026-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years and legally competent and able to understand spoken and written Danish
• Kidney transplantation ≥6 months prior (no upper limit of time after transplantation)
• Stable kidney graft function, defined as estimated GFR ≥ 30 ml/min/1.73m3
• On minimum two separate biochemical measurements:
• PTH > upper normal limit of assay and
• serum ionized calcium ≥1.33 mmol/L or
• serum total calcium ≥2.60 mmol/L or
• serum phosphate ≤0.60 mmol/L despite sufficient dietary intake
• with measurements obtained within
• 3 months in patients 6-12 months post-transplant
• 6 months in patients >12 months post-transplant
• and not attributable to calcium supplementation or treatment with thiazide diuretics or lithium.

You may not qualify if…

• Inability to provide written, informed consent
• Current anti-resorptive therapy (bisphosphonate, denosumab)
• Current bone anabolic therapy (teriparatide, romosozumab)
• Previous surgical parathyroidectomy
• Not considered fit for surgery (including pregnancy)
• Ionized calcium ≥1.50 mmol/L or albumin-corrected calcium ≥3.00 mmol/L despite discontinuation of calcium supplements.

Where it is running

• Departement of Nephrology, Aarhus University hospital — Aarhus, Central Jutland, Denmark (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.